Background/Aims: Physicians’ perception of antecedent physical/cognitive status may account for the suboptimal implementation of acute coronary syndrome (ACS) guidelines. Methods: In an ACS survey of all cardiac wards, physicians’ perception of antecedent physical/cognitive status was prospectively recorded and categorized as either normal, mildly impaired or significantly impaired. We examined the impact of antecedent status on the use of evidence-based medications and procedures and on mortality. Results: Of the 2,021 patients, 1,025 (51%) had ST elevation. Impaired antecedent physical/cognitive status was diagnosed in 417 patients (20.6%), more commonly among non-ST-elevation patients (26.2 vs. 15.2%). Patients with impaired physical/cognitive status, with or without ST elevation, had significantly worse baseline demographic and clinical characteristics. They less often received aspirin, clopidogrel, platelet glycoprotein IIb/IIIa receptor antagonists, statins and β-adrenergic blockers, and significantly less often underwent in-hospital catheterization and revascularization. Reperfusion treatment was given significantly less frequently to ST elevation patients with impaired status (63.0% for normal vs. 50.8% and 33.3% for mildly and significantly impaired status, respectively; p = 0.001). After adjustment for differences in baseline characteristics, impaired antecedent status remained independently associated with lower use of these therapies and higher mortality rates. Conclusions: ACS guideline implementation is significantly influenced by physicians’ perception of antecedent physical/cognitive status, and thus is a crucial parameter for understanding ACS management and outcomes.

Keywords:
Acute coronary syndromes, Physical/cognitive status
1.
Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2004;44:671–719.
2.
Van de Werf F, Ardissino D, Betriu A, et al: Management of acute myocardial infarction in patients presenting with ST-elevation. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28–66.
3.
Bertrand ME, Simoons ML, Fox KA, et al: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002;23:1809–1840.
4.
Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2002;40:366–374.
5.
Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh B, Geltman EM, Sollano J, Katz S, Moye L, Basta LL, et al: Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 1991;325:226–230.
6.
Krumholz HM, Douglas PS, Lauer MS, Pasternak PC: Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for gender bias? Ann Intern Med 1992;116:785–790.
7.
Clarke KW, Gray D, Keating NA, Hampton JR: Do women with acute myocardial infarction receive the same treatment as men? BMJ 1994;309:563–566.
8.
Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Leimberger JD: Thrombolytic therapy for woman with myocardial infarction: is there a gender gap? J Am Coll Cardiol 1993;22:1780–1787.
9.
Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM: Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003;114:333–335.
10.
Krumholz HM, Radford MJ, Ellerbeck EF, et al: Aspirin in the treatment of acute myocardial infarction in elderly medicare beneficiaries: patterns of use and outcomes. Circulation 1995;92:2841–2847.
11.
Rosengren A, Wallentin L, Simoons M, et al: Age, clinical presentation and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J 2006;27:789–795.
12.
Berger AK, Duval S, Krumholz HM: Aspirin, β-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201–208.
13.
Hasdai D, Haim M, Behar S, Boyko V, Battler A: Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes. Am Heart J 2003;146:832–838.
14.
Chen J, Radford MJ, Wang Y, Krumholz HM: Care and outcomes of elderly patients with acute myocardial infarction by physician specialty: the effect of comorbidity and functional limitation. Am J Med 2000;108:460–469.
15.
Inoue SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J: Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187–1193.
16.
Peterson LA, Normand SL, Druss BG, Rosenheck RA: Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities? Health Serv Res 2003;38:41–63.
17.
Solan FA, Trogdon JG, Curtis LH, Schulman KA: The effect of dementia on outcomes and process of care for medicare beneficiaries admitted with acute myocardial infarction. J Am Geriatr Soc 2004;52:173–181.
18.
Moriel M, Behar S, Tzivoni D, Hod H, Boyko V, Gottlieb S: Manangement and outcomes of elderly women and men with acute coronary syndromes in 2000 and 2002. Arch Intern Med 2005;165:1521–1526.
19.
Katz S, Akpom CA: Index of ADL. Med Care 1976;14:116–118.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.